Skip to main content

Table 1 Patient characteristics according to the rs4950928 genotype

From: Role of genetic variations of chitinase 3-like 1 in bronchial asthmatic patients

rs4950928 genotype CC (n = 270) CG (n = 90) GG (n = 21) P value
Age, years 57.6 ± 1.0 58.5 ± 1.7 55.8 ± 3.7 NS
Height, cm 158.4 ± 0.6 159.1 ± 1.0 160.4 ± 2.1 NS
Body weight, kg 59.4 ± 0.7 60.7 ± 1.2 60.8 ± 2.7 NS
Sex, n (%) 110 men (41) 41 men (46) 12 men (57) NS
Age of onset, years 42.5 ± 1.3 44.3 ± 2.2 31.1 ± 4.5 0.032
Eosinophil count/μL 300.9 ± 17.4 359.5 ± 29.9 277.6 ± 65.1 NS
IgE level, IU/mL 412.1 ± 58.0 435.2 ± 77.9 565.4 ± 233.2 NS
GINA asthma severity, n (%)
 Mild 58 (21.5) 21 (23.3) 6 (28.6)
 Moderate 105 (38.9) 33 (36.7) 12 (57.1)
 Severe 107 (39.6) 36 (40.0) 3 (14.3)
Pulmonary function
 %FVC 103.3 ± 2.0 104.3 ± 3.4 103.51 ± 9.8 NS
 FEV1, L 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.2 NS
 FEV1/FVC, % 72.9 ± 0.7 70.8 ± 1.2 70.2 ± 2.6 NS
 %FEV1 98.9 ± 1.5 98.8 ± 2.6 95.1 ± 5.3 NS
  Mild 105.8 ± 3.1 106.8 ± 5.4 91.0 ± 26.5
  Moderate 100.0 ± 2.3 100.5 ± 4.3 103.3 ± 22.6
  Severe 94.2 ± 2.3 92.5 ± 4.1 92.2 ± 33.1
 Equivalent FP CFC dose (μg/day) 382.1 ± 17.0 362.4 ± 29.3 228.0 ± 63.7 NS
  1. Data are expressed as the mean ± standard error
  2. GINA, Global Initiative for Asthma; FVC, forced vital capacity; FEV1, forced expiratory flow volume in one second; NS, not significant among the three groups; FP, fluticasone propionate; CFC, chlorofluorocarbon propellant